Get started
Author

Atsushi Uehara

ORCID: 0009-0007-5350-4316
Observed ORCID: 0009-0007-5350-4316
OpenAlex ID: A5046446574
Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma
2024 · Daisuke Ikeda, Shuichi Aikawa, et al. · Blood · 21
Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study
2024 · Daisuke Ikeda, Mitsuaki Oura, et al. · Blood Advances · 6
PDF
Analysis of baseline circulating tumor cells integrated with PET/CT findings in transplant-ineligible multiple myeloma
2023 · Daisuke Ikeda, Toshiki Terao, et al. · Blood Advances · 6
PDF
Serum B-cell maturation antigen could be a simple and accurate biomarker to identify and prognosticate monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
2025 · Masanori Toho, Daisuke Ikeda, et al. · Haematologica · 5
PDF
Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies
2024 · Daisuke Ikeda, Tatsuya Isezaki, et al. · Cancer Chemotherapy and Pharmacology · 5
PDF
Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenström macroglobulinemia
2025 · Mitsuaki Oura, Daisuke Ikeda, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
Prognostic relevance of tumor-infiltrating CD4+ cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma
2024 · Daisuke Ikeda, Mitsuaki Oura, et al. · Haematologica · 4
PDF
Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton’s tyrosine kinase inhibitor and bispecific antibody therapy
2026 · Mitsuaki Oura, Masanori Toho, et al. · Frontiers in Oncology · 2
PDF
Different Patterns of Antigen Expression in Bone Marrow and Circulating Tumor Plasma Cells in Patients with MGUS and Smoldering Multiple Myeloma
2024 · Atsushi Uehara, Fuminari Fujii, et al. · Blood · 2
Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
2024 · Rikako Tabata, Mitsuaki Oura, et al. · Blood · 2
Total Diffusion Volume Evaluated By Whole-Body Diffusion Weighted Magnetic Resonance Image for the Assessment of Tumor Burden in Multiple Myeloma; Relations with Measurable Residual Disease Evaluated By Next-Generation Flow Cytometry and Bone Marrow CD138 Staining Assessed By Qupath
2024 · Kentaro Narita, Youichi Machida, et al. · Blood · 2
PDF
Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma
2024 · Daisuke Ikeda, Shuichi Aikawa, et al. · Blood · 1
A Prognostic Model Integrating Circulating Clonal Plasma Cells into R-ISS and PET-CT Based Tumor Burden in Transplant-Ineligible Multiple Myeloma
2023 · Daisuke Ikeda, Toshiki Terao, et al. · Blood · 1
PDF
Red Cell Distribution Width-to-Albumin Ratio Is a Simple but Robust Prognostic Biomarker in Peripheral T-Cell Lymphoma
2023 · Mitusaki Oura, Daisuke Ikeda, et al. · Blood · 1
A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas
2026 · Sakurako Suma, Mamiko Sakata-Yanagimoto, et al. · Nature Communications
PDF
Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma
2026 · Masanori Toho, Rikako Tabata, et al. · Blood
Extending the prognostic value of red cell distribution width to nodal T follicular helper cell lymphoma
2026 · Mitsuaki Oura, Daisuke Ikeda, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Treatment‐specific differences in soluble B‐cell maturation antigen levels at minimum residual disease negativity in multiple myeloma
2026 · Masanori Toho, Rikako Tabata, et al. · British Journal of Haematology
SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignancies
2026 · Kensuke Matsuda, Junichiro Yuda, et al. · International Journal of Clinical Oncology
PDF
Impact of the plasma cell quantification method on the International Myeloma Working Group diagnostic criteria for MGUS/SMM
2025 · Atsushi Uehara, Hajime Sakuma, et al. · Haematologica
PDF
Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma
2025 · Atsushi Uehara, Kentaro Narita, et al. · International Journal of Hematology
Tracking MRD in multiple myeloma: Soluble BCMA reflects flow cytometry changes
2025 · Masanori Toho, Rikako Tabata, et al. · Blood
Radiomic features from PET-CT enable diagnostic and prognostic stratification in peripheral T-cell lymphoma
2025 · Hajime Sakuma, Daisuke Ikeda, et al. · Blood
PDF
Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation
2025 · Hajime Sakuma, Kentaro Narita, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Treatment with Daratumumab for Immunotactoid Glomerulopathy Associated with Plasma Cell Dyscrasia: A Report of Two Cases
2025 · Atsushi Uehara, Mitsuaki Oura, et al. · Internal Medicine
PDF
Works count: 31
Citation count: 62
H-index: 5
I10-index: 1
Year
Topic
Type